Earnings
SharkNinja Raises 2026 Outlook After Sales Climb 21.2%, With Tariff Refunds Padding Reported Profit
Adjusted profit rose 55.1% in the third quarter, while tariff-refund claims pushed reported gross margin to 59.2%.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Adjusted profit rose 55.1% in the third quarter, while tariff-refund claims pushed reported gross margin to 59.2%.
SEC Filings
The hereditary angioedema drugmaker held its ORLADEYO forecast and trimmed its adjusted operating expense outlook to $415 million to $425 million.
Earnings
The publisher's third-quarter EPS reached $0.60, and it guided fourth-quarter digital subscription revenue growth of 12% to 15%.
SEC Filings
The alopecia drug developer plans regulator talks this quarter ahead of a late-stage bempikibart program in the first half of 2027.
Earnings
Third-quarter sales rose 7% to $966.8 million, while standard-accounting earnings per share fell to $0.25 from $0.46.
Earnings
The drug-testing company lifted its adjusted EPS and organic revenue guidance; a foreign tax reversal inflated reported earnings to $6.86 a share.
Earnings
The online home retailer's U.S. sales rose 11.4% in the third quarter, and orders delivered climbed 12.2%.
SEC Filings
The drug developer holds $140.7 million in cash and says it can fund operations into the second half of 2029.
Earnings
The IT reseller's gross margin fell from 21.9% a year earlier, and operating cash flow for nine months dropped to $618.5 million.
SEC Filings
The biotech says $498.5 million in cash lasts to mid-2028, and up to $400 million more is available through a Hercules Capital debt facility.
Earnings
The solar and battery wiring maker raised its 2026 outlook as net income rose to $17.9 million, even as plant-move costs squeezed margins.
Earnings
More than 100 patients were on the thyroid eye disease drug at the end of September, while selling costs rose to $57.6 million.